| Latest Genta News Headlines |
| Date | Time | Source | |
| 05/06/2008 | 9:40AM | PRNUS | Genta Announces Pending Transfer of its Common Stock to the Over-the-Counter Bulletin Board
BERKELEY HEIGHTS, N.J., May 6 /PRNewswire-FirstCall/ -- Genta Incorporated (NASDAQ:GNTA) announced today that the Company has received notification from the NASDAQ Listing Qualifications Panel that the Company had failed to demonstrate its ability to sustain compliance with the minimum stockholders' equity requirement... More...>> |
| 04/30/2008 | 8:00AM | PRNUS | Genta Announces First Quarter 2008 Financial Results and Corporate Update
BERKELEY HEIGHTS, N.J., April 30 /PRNewswire/ -- Genta Incorporated (NASDAQ:GNTA) announced that the Company will release its first quarter 2008 financial results on Thursday, May 8, 2008. Genta management will host a conference call and live audio webcast to discuss financial results and recent corporate activities... More...>> |
| 04/14/2008 | 8:00AM | PRNUS | Genta Receives Key Patent Related to Oral Gallium Compound G4544
Company to Seek Buyer for Marketed Parenteral Product Ganite(R)
BERKELEY HEIGHTS, N.J., April 14 /PRNewswire/ -- Genta Incorporated (NASDAQ:GNTA) today announced that the Company has received notice that its patent application covering novel pharmaceutical gallium compositions and complexes has been allowed by the U.S... More...>> |
| 04/07/2008 | 8:00AM | PRNUS | Specialized Genasense(R) Clinical Trials Featured at AACR Meeting
BERKELEY HEIGHTS, N.J., April 7, 2008 /PRNewswire-FirstCall/ -- Genta Incorporated (NASDAQ:GNTA) announced that presentations related to Genasense(R) (oblimersen sodium) Injection, the Company's lead anticancer compound will be featured at the annual meeting of the American Association for Cancer Research (AACR). The... More...>> |
| 04/02/2008 | 8:00AM | PRNUS | Genta Restructures Operations to Focus on Priority Initiatives
Company to Seek Buyer for Marketed Product Ganite(R)
BERKELEY HEIGHTS, N.J., April 2, 2008 /PRNewswire-FirstCall/ -- Genta Incorporated (NASDAQ:GNTA) today announced that the Company has restructured certain of its operations to conserve cash and focus on its priority oncology development operations. In March 2008... More...>> |
| 03/31/2008 | 8:00AM | PRNUS | DSMB Supports Continuation of Phase 3 AGENDA Trial of Genasense(R) in Advanced Melanoma
Completion of Target Enrollment Expected in Fourth Quarter
BERKELEY HEIGHTS, N.J., March 31 /PRNewswire-FirstCall/ -- Genta Incorporated (NASDAQ:GNTA) announced that the Data Safety Monitoring Board (DSMB) for AGENDA, a Phase 3 trial of Genasense (oblimersen sodium) Injection, which is the Company's lead oncology product... More...>> |
| 03/27/2008 | 3:54PM | PRNUS | Genta Granted Extension to Achieve Compliance with NASDAQ Listing Requirements
BERKELEY HEIGHTS, N.J., March 27 /PRNewswire-FirstCall/ -- Genta Incorporated (NASDAQ:GNTA) announced that the NASDAQ Listing Qualifications Panel has granted the Company's request for an extension of time to achieve full compliance with the applicable NASDAQ listing requirements. Pursuant to the Panel's decision... More...>> |
| 03/20/2008 | 6:13PM | PRNUS | Auditors for Genta Incorporated Express Going Concern Qualification
BERKELEY HEIGHTS, N.J., March 20 /PRNewswire-FirstCall/ -- Genta Incorporated (NASDAQ:GNTA) announced today that in its 2007 financial statements included in the Company's Annual Report on Form 10-K, the auditor's opinion contained a "going concern" qualification. NASDAQ's marketplace rules require NASDAQ-listed companies... More...>> |
| 03/17/2008 | 8:00AM | PRNUS | FDA Indicates That Genasense(R) Approval in Chronic Lymphocytic Leukemia Will Require Additional Confirmatory Data
Approval Dependent on Outcomes of New Analyses or Confirmatory Trial
BERKELEY HEIGHTS, N.J., March 17 /PRNewswire-FirstCall/ -- Genta Incorporated (NASDAQ:GNTA) announced that the Food and Drug Administration's (FDA) Center for Drug Evaluation and Research (CDER) has decided that available data are not adequate to support... More...>> |
| 03/12/2008 | 7:00AM | PRNUS | Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights
BERKELEY HEIGHTS, N.J., March 12 /PRNewswire-FirstCall/ -- Genta Incorporated (NASDAQ:GNTA) today announced financial results and progress for the quarter and year ended December 31, 2007. The Company noted significant recent milestones, including:
-- AGENDA Phase 3 trial using key biomarker initiates in melanoma... More...>> |
| 03/07/2008 | 9:21AM | PRNUS | Genta Announces Licensing Agreement for Worldwide Development and Commercialization of a Leading Oral Taxane, Tesetaxel
BERKELEY HEIGHTS, N.J., March 7 /PRNewswire-FirstCall/ -- Genta Incorporated (NASDAQ:GNTA) announced today the Company has entered into an exclusive worldwide licensing agreement with Daiichi Sankyo Company, Limited (TYO: 4568) for the development and commercialization of tesetaxel (formerly known as DJ-927). As a... More...>> |
| 03/05/2008 | 8:00AM | PRNUS | Genta Announces Fourth Quarter and Year End 2007 Conference Call
BERKELEY HEIGHTS, N.J., March 5 /PRNewswire-FirstCall/ -- Genta Incorporated (NASDAQ:GNTA) announced today that the Company will release its financial results for the fourth quarter and year ended December 31, 2007 on Wednesday, March 12, 2008. Genta management will host a conference call and live audio webcast to... More...>> |
| 02/22/2008 | 8:00AM | PRNUS | Genta Announces Senior Management Changes
BERKELEY HEIGHTS, N.J., Feb. 22 /PRNewswire-FirstCall/ -- Genta Incorporated (NASDAQ:GNTA) today announced that Richard J. Moran, Senior Vice-President and Chief Financial Officer, has indicated his intention to retire from the Company effective February 29, 2008. Upon Mr. Moran's retirement, Gary Siegel, currently... More...>> |
| 02/11/2008 | 8:00AM | PRNUS | Genta Announces Common Stock Offering of Approximately $3.1 Million
BERKELEY HEIGHTS, N.J., Feb. 11 /PRNewswire-FirstCall/ -- Genta Incorporated (NASDAQ:GNTA) announced that the Company has entered into definitive agreements with institutional investors to sell 6 million shares of common stock through a registered offering for gross proceeds totaling approximately $3.1 million before... More...>> |
| 02/05/2008 | 8:00AM | PRNUS | Genta Incorporated to Present at the BIO CEO & Investor Conference
BERKELEY HEIGHTS, N.J., Feb. 5 /PRNewswire-FirstCall/ -- Genta Incorporated (NASDAQ:GNTA) announced today that the Company's Chairman and Chief Executive Officer, Dr. Raymond P. Warrell, Jr., will provide a company overview and update of corporate activities at the BIO CEO & Investor Conference. The presentation is... More...>> |
| 01/14/2008 | 8:00AM | PRNUS | FDA Extends Review of Genasense(R) NDA Appeal in Chronic Lymphocytic Leukemia
BERKELEY HEIGHTS, N.J., Jan. 14 /PRNewswire-FirstCall/ -- Genta Incorporated (NASDAQ:GNTA) announced today that the Food and Drug Administration (FDA) has extended its review of Genta's appeal of the non- approvable decision for a New Drug Application (NDA) that proposed the use of Genasense(R) (oblimersen sodium injection... More...>> |
| 01/11/2008 | 5:00PM | PRNUS | Genta Receives Notice of Non-Compliance With NASDAQ Rule
Company to File Appeal
BERKELEY HEIGHTS, N.J., Jan. 11 /PRNewswire-FirstCall/ -- Genta Incorporated (NASDAQ:GNTA) announced today that the Company has received notice from the Listing Qualifications Staff of The NASDAQ Stock Market that, based upon the Company's non-compliance with the stockholders' equity requirement... More...>> |
| 12/24/2007 | 4:15PM | PRNUS | Genta Receives NASDAQ Non-Compliance Notice
BERKELEY HEIGHTS, N.J., Dec. 24 /PRNewswire-FirstCall/ -- Genta Incorporated (NASDAQ:GNTA) announced today that the Company has been notified by the Listing Qualifications Staff of The NASDAQ Stock Market that it no longer complies with NASDAQ Marketplace Rule 4450(a)(5), which requires a minimum closing bid price of... More...>> |
| 12/21/2007 | 8:05AM | PRNUS | FDA to Extend Review of Data Quality Submission for Genasense(R) in Melanoma
BERKELEY HEIGHTS, N.J., Dec. 21 /PRNewswire-FirstCall/ -- Genta Incorporated (NASDAQ:GNTA) announced today that the Company has received notice from the Food and Drug Administration (FDA) that FDA has extended its review period of Genta's request for correction of certain information that was filed pursuant to the Information... More...>> |
| 12/10/2007 | 8:05AM | PRNUS | Genasense Plus Chemotherapy Is Associated With Prolonged Survival in Patients With Relapsed/Refractory CLL Who Achieve Complete
Updated Phase 3 Results Released at American Society of Hematology Meeting
BERKELEY HEIGHTS, N.J., Dec. 10 /PRNewswire-FirstCall/ -- Genta Incorporated (NASDAQ:GNTA) announced the release of new survival analyses based upon extended follow-up of patients in the Company's randomized Phase 3 trial of Genasense(R) (oblimersen... More...>> |